GLP-1 Medications: Weighing the Impact on Food Sector Investment and Strategy
The rapid rise of GLP-1 medications such as Ozempic and Wegovy has become a defining trend in both healthcare and the food industry.
Originally developed for diabetes management, these drugs are now widely used for weight loss, with profound implications for food consumption patterns, product development, and investment strategy.
The GLP-1 Effect: Market Penetration
– In the UK, 4.2 million adults—nearly 1 in 10—had recently used a GLP-1 medication or expressed interest in doing so as of early 2025
– Two in five overweight Britons (38%) express interest in using GLP-1s for weight loss when informed about the drugs
– Across Europe, the GLP-1 market is valued at €9.62 billion in 2025, with robust growth expected due to rising obesity and diabetes rates, improved access, and strong healthcare infrastructure in markets like Germany, France, and the UK
– Social acceptance is rising, and insurance coverage is likely to expand, further accelerating adoption. The rapid rise of GLP-1 medications such as Ozempic and Wegovy has become a defining trend in both healthcare and the food industry.
Impact on Food Industry Sectors
The use of GLP-1 medication is well documented, and regardless of the perceived pros and cons of usage, the fact remains that adoption is rapidly growing, and that GLP-1 users consume 15–40% fewer calories and report reduced cravings for sweet, salty, fatty, and alcoholic foods. Demand is shifting toward pre-portioned, nutrient-dense, and protein-rich foods, while indulgent snacks, sweet bakery items, and soft drinks are seeing the steepest declines.
Product Development:
– Smaller portions and “GLP-1 friendly” claims: Aligning products with new consumption patterns is essential.
– Digestive health and side-effect support: Products addressing common side effects (e.g., high-fibre, gut-friendly) are poised for growth.
– Menu innovation in foodservice: Restaurants and cafés should adapt offerings to cater to reduced appetite and new dietary preferences.
Conclusion
GLP-1 medications are already influencing food purchasing and consumption patterns in the UK and Europe, with the most pronounced impact in snack foods, indulgent categories, and foodservice. While the overall market share of GLP-1 users is still emerging, the pace of adoption and the depth of behavioural change suggest this is a trend that warrants close attention. For M&A groups, a proactive approach—focusing on health-oriented assets, reformulation, and innovation—will be key to navigating and capitalising on this evolving landscape.